Abstracts from the 2017 ASCP Annual Meeting

Monday, May 29, 2017

Latin American Symposium*

Overcoming Latino Mental Health Disparities Via Health Promotion

Identifying Patients With Bipolar Disorders in Emergency Departments in Latin-American Countries: Comorbidity and Leading Symptoms

Effect of a Novel NMDA Receptor Modulator, Rapastinel (formerly GLYX-13) in OCD: Proof-of-Concept

Atypical Antipsychotics in the Treatment of PTSD

PTSD and Gender Violence: Ecuador Experience

Pharmacological Updates in Mood Disorders

Tuesday, May 30, 2017

Tuesday Morning Panel Sessions

Implementing Measurement-Based Care in Clinical Practice*

Measurement-Based Care: A Platform for Personalized Clinical Decision-Making*

Design and Implementation of the PCARES Program: Penn State Clinical Assessment and Rating Evaluation System*

Penn State Clinical Assessment and Rating Evaluation System for Youth*

Mood Outcomes Program: National Network of Depression Centers*

The Role of Modulators of the Opioid System in the Treatment of Neuropsychiatric Illnesses*

Preclinical Evidence for Potential Therapeutic Effects of Opioid Modulators in Neuropsychiatric Conditions*

The Role of Buprenorphine/Samidorphan in the Treatment of Resistant Depression

A Clinical Development Program in Psychiatry for a Selective Kappa Antagonist*

Tramadol and Other Opioid Agents in Refractory OCD*

Inflammation and Obesity in Depression: Neurobiological Mechanisms and Therapeutic Implications*

Obesity as a Moderator of Response to Antidepressants*

Inflammation Effects on Reward Circuitry and Motivation: Treatment Considerations for Depression*

Inflammatory Biomarkers as Viable Moderators for Treatment Selection—Results From the COMED Trial*

Pharmacotherapy and Psychosocial Treatment in First Episode Psychosis Studies: Models and Outcomes*

Impact of Antipsychotic Medication Dose and Adherence on Improvement During Cognitive Remediation in Early Course Schizophrenia*

Antipsychotic Medication Effects in the Context of Psychosocial Treatments After an Initial Episode of Schizophrenia*

Psychopharmacological Treatment in the RAISE-ETP Study: A Manual and Computer Decision Support System Based Intervention Within a Comprehensive First Episode Specialty Care Program*

Tuesday Mid-Morning Panel Sessions

Targeting Treatment Needs in Women’s Mental Health*

Brief Psychotherapy for Maternal Depression: Impact on School Age Children*

Results From a Phase 2 Trial of SAGE-547 in Severe Postpartum Depression*

Risk of Depressive Relapse in Women Undergoing Treatment for Infertility*

The Development and Selected Performance of Patient Reported Outcomes (PRO) in Psychopharmacotherapy Trials—Is the Juice Worth the Squeeze? A Review of Initiatives by the FDA, NIH, and the Alcohol Clinical Trials Initiative (ACTIVE)

Patient-Reported Outcomes to Capture the Patient Voice in Drug Development: A Regulatory Perspective

Alcohol Clinical Trials Initiative (ACTIVE) Validation of a Potential Patient-Reported Outcome Measure of Alcohol-Related Consequences (the IMBIBE) and Its Use as an Endpoint in Alcohol Pharmacotherapy Trials

The Patient-Reported Outcomes Measurement Information System (PROMIS) Program: An NIH-Funded Effort to Develop a Psychometrically-Sound PRO Item Bank: Tobacco and Alcohol Banks

Model-Based Approaches to Assist Clinical Development of Psychiatric Products

Exposure-Response Analysis of Blood Pressure and Heart Rate Changes for Methylphenidate in Healthy Adults

Population Pharmacokinetic Modeling and Simulation to Determine Dosing Strategies for Long Acting Injectable Antipsychotics

Shortening the Duration of Acute Schizophrenia Registration Trials Is a Possibility

Development of Antidepressants With Novel Mechanisms of Action*

The Neurogenic Antidepressant Compound, NSI-189, Shows Potential as a Broad Neurotrophic Agent*

The Potential Therapeutic Role of Anti-Inflammatory Agents for Mood Disorders*

Synaptic and Extrasynaptic GABA-A Receptors as Drug Targets in Postpartum Depression and Major Depressive Disorder: Development of Two Positive Allosteric Modulators*

NIH Diversity Supplement Program

NIH Diversity Supplement Session*

Pharmaceutical Pipelines

A Phase Ib Dose Ranging Study of Direct Nose to Brain Delivery of Neuropeptide Y in Patients With Posttraumatic Stress Disorder

Low-Dose Bedtime Sublingual Cyclobenzaprine (TNX-102 SL*) for the Treatment of Military-Related PTSD: Retrospective Analyses of the Mediators and Moderators of Treatment Response

Double-Blind, Placebo-Controlled Study of the Novel Therapeutic AEVI-001 in Adolescents With ADHD and Glutamatergic Network Gene Mutations

SAGE-547 and SAGE-217: Novel Positive Allosteric Modulators of Synaptic and Extrasynaptic GABA-A Receptors Being Investigated in the Treatment of Mood Disorders

Double-Blind, Placebo-Controlled Trial of Ketamine Therapy in Treatment-Resistant Depression (TRD)

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 6-Week Study to Evaluate the Efficacy and Safety of TAK-063 in Subjects With an Acute Exacerbation of Schizophrenia

Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Cardiac Safety of Extended-Release Viloxazine (SPN-812 ER) in Healthy Adult Subjects

Rationale for the Clinical Development of ITI-214, a PDE1 Inhibitor

Results of a Double-Blind, Placebo-Controlled, Tolerability Study of KarXT: A Novel Combination Targeting Muscarinic Acetylcholine Receptors Using Xanomeline With Trospium Chloride to Mitigate Cholinergic Side Effects

Long-Term Efficacy and Safety of Extended-Release Molindone (SPN-810) to Manage Impulsive Aggression in Children With Attention-Deficit/Hyperactivity Disorder

Bremelanotide (BMT) for Hypoactive Sexual Desire Disorder (HSDD): Efficacy Analyses From the Reconnect Study

Individual Research Reports

Advances in Schizophrenia Treatment and Assessment*

Risk Factors for Suicidality in Patients With Schizophrenia: A Systematic Review, Meta-Analysis, and Meta-Regression*

Assessing Functional Capacity Using the UCSD Performance-Based Skills Assessment (UPSA-2-VIM) and the Virtual Reality Functional Capacity Assessment Tool (VRFCAT)*

Schizophrenia Polygenic Risk Score Predicts Antipsychotic Treatment Response in Patients With First Episode Psychosis*

Lumateperone (ITI-007): Late Stage Clinical Program in Schizophrenia*

Understanding and Optimizing Treatments for Special Populations: Hypersomnolence, Binge Eating Disorder, Pregnant Women With Depression, and Bipolar Depressive Episodes With Psychosis*

Treatment Outcomes of Acute Bipolar Depressive Episode With Psychosis*

Optimizing Medication Management for Pregnant Women With Depression*

Dasotraline for the Treatment of Moderate to Severe Binge Eating Disorder in Adults: Results From a Randomized, Double- Blind, Placebo-Controlled Study*

The Prevalence and Correlates of Hypersomnolence and Associated Role Impairment in the National Co-Morbidity Survey Replication (NCS-R)*

Focus on Neurocognition, Neurodegeneration, and Alcohol Misuse*

Trauma Exposure Moderates the Genetic Overlap Between Alcohol Misuse and Bipolar Disorders in US Army Soldiers*

The Relationship Between Cognitive and Functional Performance and Measures of Neurodegeneration Among Hispanic and White Non-Hispanic Individuals With Normal Cognition, Mild Cognitive Impairment, and Dementia*

Hazardous Alcohol Intake Alters Brain, Autonomic and Hypothalamic-Pituitary-Adrenal Axis Responses to Stress*

The Impact of Cerebral Small Vessel Disease in Alzheimer’s Disease and Other Late Life Neurocognitive Disorders*

Treatment Adherence to Atypical Antipsychotic Medications, Ketamine, and Screening for Psychiatric Disorders*

Differential Adherence to Antipsychotic Medication Impacts Clinical and Functional Outcomes in Antipsychotic-Naïve First-Episode Psychosis Patients: A Longitudinal Study*

A Web-Based Survey of the Clinical, Off-Label Use of Ketamine as a Treatment for Psychiatric Disorders*

Screening for Psychiatric Disorders With Self-Administered Questionnaires*

Measuring the Relationship Between Patient Adherence to Atypical Antipsychotics and Their Other Medications*

Wednesday, May 31, 2017

Regulatory Plenary Session

Regulatory Plenary

ASCP Awards Ceremony and ASCP Lifetime Awardee Talk—David Kupfer: After Fifty Years, All Roads Converge

After Fifty Years, All Roads Converge

Wednesday Afternoon Panel Sessions

Impact of Abnormal Involuntary Movements Across Diverse Clinical Populations*

Prevalence of Akathisia, EPS and TD Across Agents and Patient Populations*

Who's at Risk for Drug-Induced Movement Disorders? A Focus on Diversity of Patient Risk Factors and Clinical Presentations*

Treatment Adherence and Antipsychotic-Related Adverse Effects*

Current and Emerging Treatments for Drug Induced Movement Disorders*

Optimizing Neuromodulatory and Pharmacologic Approaches to Treatment Refractory Depression*

Pharmacological Strategies in the Treatment of Resistant Depression

Optimizing Transcranial Magnetic Stimulation (TMS) Therapy for TRD*

Strategies for Optimizing ECT: Integration of Pharmacology, Anesthesia and Stimulus Parameters*

Regulatory and Methodological Considerations in the Evaluation of Drug Dependence in the Clinical Setting

Regulatory Considerations in the Assessment of Drug Dependence and Withdrawal in Humans.

Clinical Methods to Evaluate Physical Dependency and Withdrawal Following Abrupt Drug Discontinuation

Practical Considerations Regarding the Administration of Pharmacodynamic Measures to Evaluate Physical Dependency and Withdrawal Following Abrupt Drug Discontinuation

Medication or Psychotherapy as First-Line Treatment for Posttraumatic Stress Disorder? An Update on the Clinical Practice Guidelines for the Prevention and Treatment of PTSD*

An Evidence Based Review of Early Intervention and Prevention of Posttraumatic Stress Disorder*

An Evidence Based Review of Psychotherapy Interventions for Treatment of Posttraumatic Stress Disorder*

Clinical Practice Guidelines for the Pharmacotherapy of Posttraumatic Stress Disorder*

Translating the Facilitation or Impairment of Fear Acquisition and Extinction Memories in Trauma-, Stressor-, and Anxiety-Related Disorders: Implications for PTSD Treatment*

FDA 101 Session

Care and Feeding of an Investigational New Drug (IND)

Wednesday Afternoon Workshops

Hot Button Topics in Negotiation for Mid-Career Professionals in Psychopharmacology and Allied Fields*

Novel Applications of Ketamine*

Intravenous Ketamine for the Treatment of Comorbid Pain and Depression*

Ketamine for Treatment of Depression in Parkinson’s Disease*

The Challenges of Maintenance and Relapse Prevention After Ketamine IV: The Role of Sublingual Ketamine*

Reducing Health Disparities by Promoting Functional and Life-Satisfaction Assessments in Research and Clinical Practice: Consensus Guidelines to Enhance Measurement-Based Care of Depression*

Work and Non-Work Related Productivity Improvement With Antidepressant Medications Predicts Long-Term Clinical Outcomes in Outpatients With Major Depressive Disorder*

Changes in Life-Satisfaction With Antidepressant Treatment Predict Long-Term Clinical Outcomes*

Policy Implications for Treatment Outcomes of Depressed Patients From Low-Income and Minority Populations

Tardive Dyskinesia: The Forgotten Adverse Event*

What Is the Current Prevalence and Incidence of Tardive Dyskinesia?*

Do Psychiatric Residents Underrecognize Tardive Dyskinesia?*

Treatment Landscape of Tardive Dyskinesia: What Works, What Doesn't, and Why*

New Pharmacologic Interventions for Tardive Dyskinesia: An Update*

Thursday, June 1, 2017

Keynote Plenary

Keynote Plenary Session*

Overcoming Disparities in Treatment Engagement Across Diverse Populations*

The Social Determinants of Mental Health: What? Who? and How?*

People/Participants/Patients at the Center: Re-Engineering Psychopharmacology Trials*

Federal Agency Directors Plenary

Federal Agency Directors Plenary Session

NIAAA Update

NINDS Update

An Update From the NIMH

NIDA Updates

NIH Center for Scientific Review—Update

Research Funding in Mental Health at PCORI

DOD Updates

Psychopharmacology State-of-the-Art Updates

Psychopharmacology State-of-the-Art Updates

Schizophrenia: What’s New in 2017?*

Update on the Anxiety Disorders*

Update on Neuromodulation in Psychiatry: NIMH and Brain Initiative Priorities*

Thursday Afternoon Workshops*

Rapid-Acting Antidepressants: Perspective on Issues in Nonclinical and Clinical Development From the Division of Psychiatry Products (DPP), Food and Drug Administration

Rapid-Acting Antidepressants: Perspective on Issues in Nonclinical and Clinical Development From the Division of Psychiatry Products, Food and Drug Administration

Rapid-Acting Antidepressants: Clinical Trial Design Considerations

Rapid-Acting Antidepressants: Selection and Timing of Efficacy Endpoints

Rapid-Acting Antidepressants: Clinical Trial Assessments, Interventions and Procedures to Enhance Subject Safety

Rapid-Acting Antidepressants: Expedited Programs for Serious Conditions

How to Use the Model Psychopharmacology Curriculum in Various Teachings

Psychotropics and Pregnancy: Current Practice to Evidence Based Approaches*

Mood Symptoms in Pregnant Women With Bipolar Disorder: How Effective Is Psychotropic Treatment?*

Risk-Benefit Analysis of Psychotropic Use in Pregnancy: Practical Guidelines for Clinicians From a Forensic Perspective*

New Approaches to the Design and Analysis of Studies Evaluating the Safety of Psychotropic Medications During Pregnancy*

Obstetrical Physiology and Its Impact on Pharmacokinetics*

Pharmacokinetics of Lamotrigine and Lithium Across Pregnancy: Evidence to Inform Dose Optimization

Friday, June 2, 2017

Friday Morning Panel Sessions

Validly and Reliably Measuring Functional Performance in Dementia Patients Across Countries and Languages in Clinical Trials

Measuring Functional Performance in Individuals on the Dementia Continuum: What to Consider

Linguistically Validating the Disability Assessment in Dementia (DAD) for Use in International Clinical Trials

Training and Monitoring Clinicians Administering Functional Assessments in Dementia Global Trials

Suicidal Behavior in the Clinical Setting: Relationship Between ADHD, Depression, and Decision-Making Capacity*

Phenotypes of Suicidality in Depressed Patients*

Chronic Anhedonia: A Risk Factor for Attention Deficit Hyperactivity Disorder and Suicidal Behavior in Depressed Adults*

Neurobiological Variance in Suicide Attempt and Ideation: Clinical and Treatment Implications*

New Technologies for Reducing Placebo Response and Improving Signal Detection in CNS Clinical Trials

NEWMEDS Data on Duplicate and Sequential Enrollment in Clinical Trials and Online Registry to Reduce Duplicate and Sequential Enrollment

Learning From a Computer Simulated Rater: Lessons in Signal Detection

Clinical Trial Design, Conduct and Analysis Methodology Options to Reduce Risk, Time, Cost, and Enable Signal Detection in the Presence of High Placebo Response and Variability in Neuroscience

Expectation Bias and Variance: Challenges to CNS Trial Signal Detection and Some New Technologies to Minimize Them

Neuromodulation With Transcranial Near-Infrared Light: Controlled Evidence*

Transcranial Photobiomodulation for Brain Disorders*

Cognitive Deficits and Mitochondrial Dysfunction in Mood Disorders—The Rationale for Transcranial Photobiomodulation*

Transcranial Photobiomodulation in Major Depressive Disorder*

Significant Improvement in Cognition in Mild to Moderately-Severe Dementia Cases Treated With Transcranial Plus Intranasal Photobiomodulation: Case Series Report

*Of special interest to clinicians